Safety and Dose-Response of Bletilla Formosana in Prediabetic Subjects

ClinicalTrials.gov ID

NCT07704944

Lead Sponsor

Chang Gung Memorial HospitalOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Phase 1Phase 2

Enrollment

94Estimated

Last Update Posted

Jul 15, 2026Actual

Start Date

Jul 1, 2026Estimated

Primary Completion Date

Jul 1, 2027Estimated

Completion Date

Aug 1, 2027Estimated

Official Title

A Phase I/II Randomized, Double-Blind, Placebo-Controlled Pilot Trial Evaluating the Safety and Dose-Response of Bletilla Formosana in Prediabetic Subjects

Brief Summary

This study evaluates the safety and preliminary efficacy of Bletilla formosana (BF), a traditional herbal medicine, in adults with prediabetes. Prediabetes is a high-risk condition where blood sugar levels are elevated, often leading to type 2 diabetes. While lifestyle changes are the standard treatment, researchers are exploring herbal supplements as a complementary way to support metabolic health. Preclinical research has shown that BF possesses anti-inflammatory properties and may help regulate blood glucose. Participants in this study will be randomly assigned to receive either a high dose of BF, a low dose of BF, or a placebo (an inactive substance) for 12 weeks. The total study duration is approximately 24 weeks, involving four clinic visits for blood tests and safety monitoring to see how BF affects blood sugar markers and inflammation.

Detailed Description

This is a single-center, Phase I/II, randomized, double-blind, placebo-controlled, parallel-design trial. The primary goal is to translate robust preclinical findings-where BF extract was shown to inhibit neutrophil-driven inflammation and improve glycemic parameters in animal models-into clinical evidence.

A total of 94 prediabetic subjects (defined by FPG 100-125 mg/dL or HbA1c 5.7%-6.4%) will be enrolled.

Participants will be randomized in a 2:2:1 ratio into one of the following three arms:

High-dose group: 3g Bletilla formosana powder daily. Low-dose group: 1.5g Bletilla formosana powder plus 1.5g placebo daily. Placebo group: 3g inactive placebo powder daily.

The study consists of three distinct phases:

Screening Phase: Up to 2 weeks for eligibility confirmation. Treatment Phase: 12 weeks of oral administration. Follow-up Phase: 12 weeks post-treatment to evaluate sustained efficacy and safety outcomes.

Phase I objectives focus on safety and tolerability, with adverse events (AEs) and serious adverse events (SAEs) graded according to CTCAE v5.0.

Phase II objectives explore preliminary efficacy through changes in fasting plasma glucose (FPG), HbA1c, and HOMA-IR.

Secondary endpoints include assessment of inflammatory biomarkers (TNF-α, IL-6, and CRP) and lipid profiles.

Clinical assessments, including 12-lead ECG and comprehensive laboratory testing, are scheduled at Screening, Week 6, Week 12 (end of treatment), and Week 24 (end of study).

• Prediabetes

• Bletilla formosana (BF) powder
• Placebo

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Adults aged 30-70 years.
2. Prediabetes defined by any of the following:
3. Fasting Plasma Glucose (FPG) of 100-125 mg/dL, or
4. Glycated hemoglobin (HbA1c) of 5.7%-6.4%.
5. Willingness to provide written informed consent and comply with study procedures.

Exclusion Criteria:

1. Established type 1 or type 2 diabetes mellitus, or recent use of oral antidiabetic agents or insulin (within 3 months).
2. Abnormal liver function, defined as Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) exceeding 2-fold the upper reference limit (≥2 × ULN) at screening.
3. Abnormal renal function, defined as serum creatinine (Cr) >1.5 mg/dL or Estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73 m².
4. Gastrointestinal disorders that may affect drug absorption, such as gastrostomy, enterostomy, severe chronic diarrhea, or malabsorption syndrome.
5. Severe comorbidities within the past 6 months, including major stroke, myocardial infarction, major trauma, or major surgery.
6. Recent use of medications (within 1 month) that may significantly alter blood glucose or lipids, such as systemic corticosteroids or non-stable doses of lipid-lowering agents.
7. Malignant tumor under active treatment, or immunodeficiency/autoimmune disorders requiring immunosuppressive therapy.
8. Psychiatric disorders or cognitive impairment that may affect protocol compliance.
9. Active use of other investigational drugs within 3 months prior to screening.
10. Pregnancy or lactation.

Primary Purpose

Treatment

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Triple

Lead Sponsor

Chang Gung Memorial HospitalOTHER

Collaborators

National Science and Technology CouncilFED

8705016@cgmh.org.tw+886-975366119

8705016@cgmh.org.tw+886-975366119

• Single Dose Study of PF-04991532 in Healthy Subjects

  NCT01102673

  CompletedInterventionalPhase 1Updated Aug 5, 2010
• Trial of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes

  NCT02146157

  CompletedInterventionalNot ApplicableUpdated Oct 14, 2015
• RCT of a Polyherbal Dietary Supplement for Prediabetes

  NCT03388762

  CompletedInterventionalNot ApplicableUpdated Jun 28, 2022
• The Effect of Insoluble Yeast Beta-glucan Intake on Pre-diabetic Patients

  NCT03495362

  Unknown statusInterventionalNot ApplicableUpdated Apr 12, 2018
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus

  NCT04889157

  CompletedInterventionalPhase 1Updated Oct 1, 2024
• The Effects of Dietary Supplements on Glycemic Control, Body Composition and Hepatic Fat Content in People With Prediabetes

  NCT06437938

  Unknown statusInterventionalNot ApplicableUpdated May 31, 2024